[Ip-health] Launch : "Observatoire de la transparence dans les politiques du médicaments"

Salomé Meyer advocacy at canceralliance.co.za
Thu Jun 13 00:35:20 PDT 2019

Well done Pauline for this initiative!

It may inspire all of us to work on this - perhaps set some key objectives
with timelines. Would be wonderful if all communication could be translated
as well in English so that we can share as best practice.

Mooi loop

Salomé Meyer

Project manager: Access to Medicine campaign

Mobile l +27 079 483 3175

Work l + 27 021689 1942

Skype l salomemeyer

Twitter l @Cancer_ZA

Facebook l Salomé Meyer

Web: www.canceralliance.co.za

On Thu, 13 Jun 2019 at 09:25, Pauline Londeix <pauline.londeix at gmail.com>

> [Apologizes for cross-posting]
> Dear colleagues and friends,
> I am thrilled to share with you the announcement of the launch of the
> "Observatoire de la transparence dans les politiques du médicaments"
> (https://twitter.com/OTMeds), an organization based in France to
> monitor the implementation of the WHO transparency resolution in
> France. The resolution that was adopted by the World Health Assembly
> in May 2019, calls on countries to implement transparency on medicines
> prices. The French government also showed its support to this initial
> text proposed for the resolution going further than prices, and we now
> want full transparency to be implemented in France.
> Transparency is critical for countries like France to face the
> unstoppable increases in medicines prices and to sustain their health
> systems.
> Besides monitoring the advancement on the implementation of the
> transparency resolution in pricing, clinical trials, research and
> development, marketing and patenting, the Observatory will also
> monitor the position of France within the international institutions
> (WIPO, WTO, WHO, etc), as well as at the European level, in particular
> as part of the European Commission (EC) negotiating Free Trade
> agreements such as MERCOSUR, Tunisia and Morocco. These agreements
> currently in negotiation include, on the request of the EC, provisions
> such as data exclusivity and trade secrets, that go in the opposite
> direction to transparency.
> While high medicines' prices jeopardize the sustainability of our
> public health systems and also delay access to many new medicines,
> they also put many life-saving medicines out of reach of millions in
> low and middle income countries. Medicines are developed thanks to a
> large contributions from taxpayers. It is unjust that the benefits are
> only private. We believe that it is time for public interests to
> prevail on corporations' interests and to change the narrative. These
> are our drugs !
> The observatory will work hand in hand with local and international
> NGO partners.
> Best regards,
> Pauline Londeix
> Co-founder
> --
> You received this message because you are subscribed to the Google Groups
> "Access to Medicines & Innovation" group.
> To unsubscribe from this group and stop receiving emails from it, send an
> email to accesstomedsandinnovation+unsubscribe at googlegroups.com.
> To post to this group, send email to
> accesstomedsandinnovation at googlegroups.com.
> To view this discussion on the web visit
> https://groups.google.com/d/msgid/accesstomedsandinnovation/CAE5So8EVO21B-%2Bhs4sadF-H7QU%3DMfRmHMsjbrxmbYG41qEXxZw%40mail.gmail.com
> .
> For more options, visit https://groups.google.com/d/optout.

More information about the Ip-health mailing list